SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001558370-23-000467
Filing Date
2023-01-24
Accepted
2023-01-24 16:01:58
Documents
14
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-K/A otlk-20220930x10ka.htm   iXBRL 10-K/A 577021
2 EX-31.3 otlk-20220930xex31d3.htm EX-31.3 6640
3 EX-31.4 otlk-20220930xex31d4.htm EX-31.4 6484
  Complete submission text file 0001558370-23-000467.txt   826437

Data Files

Seq Description Document Type Size
4 EX-101.SCH otlk-20220930.xsd EX-101.SCH 3165
5 EX-101.LAB otlk-20220930_lab.xml EX-101.LAB 24815
6 EX-101.PRE otlk-20220930_pre.xml EX-101.PRE 15561
8 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20220930x10ka_htm.xml XML 8311
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-K/A | Act: 34 | File No.: 001-37759 | Film No.: 23548145
SIC: 2836 Biological Products, (No Diagnostic Substances)